Shineway Pharma (02877) saw its share price spike as much as 12% in the afternoon session before settling at a 4.92% gain, trading at HKD 8.33 with turnover reaching HKD 54.234 million.

The company released its interim results, reporting H1 revenue of RMB 1.181 billion, a year-on-year decrease of 28.5%. Profit for the period stood at RMB 469 million, down 23.7% from the prior year, with basic earnings per share of RMB 0.62. The board has declared a second interim dividend of RMB 0.80 per share.

According to the company's announcement, the overall gross margin contracted from 72.2% in the same period last year to 69.9%, driven by lower sales volumes, price reductions resulting from centralized procurement, and persistently high production costs.

The group continues to prioritize the expansion of oral formulations as its core growth strategy. During the first six months of 2026, oral products accounted for 72.9% of total sales, while injection products represented the remaining 27.1%.